ADTX

​Aditxt, Inc. (NASDAQ: ADTX) is a biotechnology company focused on developing and commercializing technologies that monitor and modulate the immune system to improve health. Founded in 2017 and headquartered in Richmond, Virginia, Aditxt's innovation portfolio includes Adimune, Inc., which is developing therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying and commercializing new treatments for infectious diseases; and Pearsanta, Inc., offering personalized lab testing services. ​BioPharmCatalyst+14StockAnalysis+14Seeking Alpha+14WSJ+2FT Markets+2Reuters+2

Over the past 52 weeks, Aditxt's stock has experienced significant volatility, with a high of $54,500.00 and a low of $4.11. ​Investing.com+5INDmoney+5Yahoo Finance+5

As of March 18, 2025, the stock closed at $7.50, reflecting a 71.62% increase from the previous close. ​WSJ

Analyst sentiment toward Aditxt is mixed. According to ChartMill, out of 8 analysts, 80% recommend a "Buy," indicating a mildly positive outlook. However, Barchart.com reports a "Strong Sell" consensus based on current analyst ratings. ​Stock Screener+17INDmoney+17Seeking Alpha+17Stock ScreenerBarchart.com

Subscribe to our API. See Strong Buy and Sell Signals the Day after They Occur!